A patient on venlafaxine 150 mg daily and propranolol 60 mg daily continues to have anxiety; what should be the next step in treatment?

Management of Persistent Anxiety Despite Venlafaxine 150 mg and Propranolol 60 mg Daily

Increase venlafaxine to 225 mg daily, as the patient is on a suboptimal dose and higher doses (up to 225 mg/day) have demonstrated superior efficacy for anxiety disorders. 1, 2

Rationale for Dose Optimization

The current venlafaxine dose of 150 mg daily is below the therapeutic range typically needed for anxiety disorders:

• Venlafaxine demonstrates dose-dependent efficacy for generalized anxiety disorder, with optimal response rates at 150-225 mg/day 1, 3, 2
• Studies show that 200-225 mg/day produces significantly earlier onset of clinical improvement (as early as 1-2 weeks) compared to lower doses 3
• The FDA-approved dosing for anxiety allows titration up to 225 mg/day, with some evidence supporting tolerability up to 375 mg/day in treatment-resistant cases 1, 4, 5

Propranolol's Limited Role

Propranolol should not be relied upon as a primary anxiolytic agent:

• Beta-blockers lack robust evidence for efficacy in generalized anxiety disorder, panic disorder, or social anxiety disorder 6, 7
• A 2025 meta-analysis found no beneficial effect of beta-blockers compared to placebo or benzodiazepines for social phobia or panic disorder 7
• Propranolol is primarily useful for performance anxiety (situational use) rather than chronic anxiety disorders 1
• Consider discontinuing propranolol if it was intended as a primary anxiolytic, as it adds minimal therapeutic benefit while potentially causing side effects 6, 7

Specific Titration Strategy

Increase venlafaxine using the following approach:

• Increase by 75 mg increments every 3-7 days as tolerated 1
• Target dose: 225 mg daily (given once daily with extended-release formulation) 1
• Monitor blood pressure at each dose increase, as venlafaxine can cause dose-dependent hypertension (7-13% incidence at doses >300 mg/day) 4
• Allow 4-6 weeks at the target dose to assess full therapeutic response 1

Monitoring Requirements

Essential monitoring during dose escalation:

• Blood pressure and heart rate at baseline and with each dose adjustment 1, 4
• Emergence of activation symptoms (anxiety, agitation, insomnia) particularly in the first 1-2 weeks 4
• Suicidal ideation, especially in patients under age 25 4
• Gastrointestinal symptoms (nausea occurs in up to 37% but typically improves with continued treatment) 3

If Inadequate Response at 225 mg

Consider these sequential steps if anxiety persists after 4-6 weeks at 225 mg/day:

1. Increase to 300-375 mg/day if tolerated, though evidence beyond 225 mg is more limited 1, 5
2. Switch to duloxetine 60-120 mg/day, the only SNRI with FDA approval for generalized anxiety disorder in both adults and children 1, 8
3. Switch to an SSRI (escitalopram 10-20 mg or sertraline 50-200 mg), as SSRIs and SNRIs show equivalent efficacy with high-certainty evidence 9, 10
4. Add cognitive behavioral therapy (CBT), which has equivalent efficacy to pharmacotherapy and provides additive benefits when combined 1, 10

Critical Pitfalls to Avoid

• Do not add benzodiazepines as a first-line augmentation strategy; optimize SNRI/SSRI dosing first 10
• Do not abruptly discontinue venlafaxine if switching medications—taper over 1-2 weeks to avoid discontinuation syndrome (dizziness, paresthesias, anxiety, nausea) 4
• Do not assume treatment failure before allowing adequate time (4-6 weeks) at therapeutic doses 1
• Do not overlook comorbid conditions (depression, substance use) that may require concurrent treatment 1